HINGE HEALTH INC.

Hinge Health’s stock rose to an all-time high of $93.37, about 1% below its 52-week high. The shares gained roughly 60.55% over the past year; market capitalization is $7.25 billion with nearly 50% revenue growth in the last twelve months. Hinge Health beat expectations in the second quarter with earnings of $0.59 per share and revenue of $212.8 million (+53%), doubled operating income to $62 million and raised its 2026 guidance. The company is expanding via the acquisition of Cylinder Health for $105 million; several analysts subsequently raised price targets. » Plus sur de.investing.com

Hinge Health shares climbed to an all-time high of $91.54 and are currently at $91.51 with a market capitalization of $7.21 billion. Over the past year the stock rose 62.8%, gained 170% in the last six months and is up 92% year-to-date. Hinge Health beat expectations in the second quarter (EPS $0.59 vs. $0.13; revenue +53% to $212.8 million), raised its full-year guidance and announced the $105 million acquisition of Cylinder Health. Analysts raised price targets (including Truist $112, Citizens $107, Stifel $96), while InvestingPro warns of overvaluation and an overbought RSI. » Plus sur de.investing.com

Hinge Health reported Q2/2026 revenue of $212.8m (+53% y/y) and adjusted diluted EPS of $0.59 versus consensus $0.13. Free cash flow rose to about $100m (margin 47% vs. 23% a year earlier) and the 2026 revenue guide was raised to $818–824m; the Q3 guide is $223–225m, above analyst consensus. At the same time, Hinge Health announced the acquisition of Cylinder Health for $105m in cash, expected to close in Q3 and to enable a gastroenterology program in 2027; several analysts subsequently raised their price targets. » Plus sur de.investing.com